Stockscreener 앱 받기
10.15
5.40%
0.52
시간 외 거래:
10.10
-0.05
-0.49%
Regenxbio Inc 주식(RGNX)의 최신 뉴스
Regenxbio Sets Sights On 2026 Filing For DMD Gene Therapy - Citeline
FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - BioPharma Dive
REGENXBIO (NASDAQ:RGNX) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Regenxbio surges 10% as it launches pivotal phase of muscular dystrophy asset trial - Seeking Alpha
What's Going On With REGENXBIO Shares Monday? - Benzinga
Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion - MarketWatch
Regenxbio (RGNX) Initiates Pivotal Phase Of Affinity Duchenne® Trial Of Rgx-202 Gene Therapy And Reports Positive Functional Data - StreetInsider.com
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - Yahoo Finance
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
REGENXBIO (NASDAQ:RGNX) Shares Gap Up – Should You Buy? - Defense World
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Regenxbio down 13% ahead of data readout for muscular dystrophy asset - Seeking Alpha
REGENXBIO (NASDAQ:RGNX) Shares Gap UpWhat's Next? - MarketBeat
Redmile Group, LLC Increases Stake in Regenxbio Inc - GuruFocus.com
5 Analysts Have This To Say About Regenxbio - Benzinga
REGENXBIO's (RGNX) Overweight Rating Reaffirmed at Morgan Stanley - MarketBeat
REGENXBIO to Present First Functional Data for Novel Duchenne Gene Therapy RGX-202 | RGNX Stock News - StockTitan
REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India
REGENXBIO FY2024 EPS Estimate Reduced by Leerink Partnrs - Defense World
REGENXBIO (NASDAQ:RGNX) Price Target Raised to $40.00 at HC Wainwright - Defense World
HC Wainwright Has Positive View of REGENXBIO FY2024 Earnings - MarketBeat
HC Wainwright Increases Earnings Estimates for REGENXBIO - Defense World
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report - Yahoo Finance
REGENXBIO Inc. (NASDAQ:RGNX) Q3 2024 Earnings Call Transcript - Insider Monkey
REGENXBIO Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ... - Yahoo Finance
Regenxbio: Q3 Earnings Snapshot - The Washington Post
RegenXBio Reports Progress Amid Revenue Decline - TipRanks
Regenxbio Inc earnings missed by $0.05, revenue topped estimates - Investing.com Australia
REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates - StockTitan
Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Vanguard Group Inc's Strategic Reduction in Regenxbio Inc Holdin - GuruFocus.com
Sorrento Therapeutics (OTCMKTS:SRNEQ) & REGENXBIO (NASDAQ:RGNX) Financial Survey - Defense World
REGENXBIO to Participate in Upcoming Investor Conferences - StockTitan
When (RGNX) Moves Investors should Listen - Stock Traders Daily
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track (NASDAQ:RGNX) - Seeking Alpha
REGENXBIO (RGNX) to Release Quarterly Earnings on Wednesday - MarketBeat
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights - cnhinews.com
Assenagon Asset Management S.A. Lowers Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
RGNX stock touches 52-week low at $9.1 amid market challenges By Investing.com - Investing.com South Africa
RGNX stock touches 52-week low at $9.1 amid market challenges - Investing.com
SG Americas Securities LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
How the (RGNX) price action is used to our Advantage - Stock Traders Daily
REGENXBIO (NASDAQ:RGNX) Rating Reiterated by Chardan Capital - Defense World
The past five years for REGENXBIO (NASDAQ:RGNX) investors has not been profitable - Yahoo Finance
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan Capital - MarketBeat
3.66%
1.11%
자본화:
|
볼륨(24시간):